MedTech Innovator

MedTech Innovator

Paul Grand founded MedTech Innovator in 2013, structuring it as a 501(c)(3) nonprofit that receives funding from a consortium of more than 20 large medical device and health technology corporations rather than from limited partner capital. The model replaced the traditional equity-for-services trade with an open innovation framework: corporate sponsors gain early visibility into vetted startups while the companies retain full ownership and receive mentorship from senior industry executives. MedTech Innovator runs an annual competition that selects roughly 50 startups from over 1,000 applicants. Cohort companies participate in a four-month virtual curriculum before advancing to an in-person showcase at The MedTech Conference — an event historically organized by the Advanced Medical Technology Association (AdvaMed). The program has produced notable exits including the acquisition of Digital Surgery by Medtronic and the public listing of HeartFlow on the Nasdaq. Investment activity spans cardiovascular devices, minimally invasive surgery platforms, neurotechnology, and diagnostics, with geographic reach concentrated in North America but increasingly involving European and Israeli startups through regional partnerships. The organization's funding comes from corporate sponsors that have included Johnson & Johnson, Medtronic, Stryker, Intuitive Surgical, and Siemens Healthineers, among others. Paul Grand, a former venture capital partner and medical device entrepreneur, serves as CEO. A dedicated analyst team vets applications alongside a network of hundreds of evaluators drawn from the medical device industry. While primarily virtual, the organization maintains operational presences in Los Angeles and Denver. In 2023, MedTech Innovator expanded its programming to include targeted tracks for pediatric medical devices and digital health solutions. MedTech Innovator departs fundamentally from the typical venture studio or accelerator model. It takes no equity and charges no fees to portfolio companies. Instead, corporate sponsors pay for access to an exclusive, continuously refreshed innovation pipeline — effectively a shared diligence platform. This makes MedTech Innovator less a capital allocator and more an industry-backed matchmaking utility between early-stage device companies and the multinational strategics that control downstream distribution and regulatory infrastructure.